Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis

Ferenc Emil Mózes, Jenny A Lee, Emmanuel Anandraj Selvaraj, Arjun Narayan Ajmer Jayaswal, Michael Trauner, Jerome Boursier, Céline Fournier, Katharina Stauffer, Rudolf E Stauber, Elisabetta Bugianesi, Ramy Younes, Silvia Gaia, Monica Lupșor-Platon, Salvatore Petta, Toshihide Shima, Takeshi Okanoue, Sanjiv Mahadeva, Wah-Kheong Chan, Peter J Eddowes, Gideon M Hirschfield, Philip Noel Newsome, Vincent Wai-Sun Wong, Victor de Ledinghen, Jiangao Fan, Feng Shen, Jeremy F Cobbold, Thomas Karlas, Yusuf Yilmaz, Guruprasad Padur Aithal, Christian Labenz, Won Kim, Myoung Seok Lee, Johannes Wiegand, Thomas Carlsson, Yusuf Yilmaz, Katharina Staufer, Akira Okajima, Jörm M Schattenberg, Sandeep Aggarwal, Harshit Garg, Geraldine J Ooi, Atsushi Nakajima, Marianne Ziol, Nathalie Barget, Andreas Geier, Theresa Tuthill, M. Julia Brosnan, Quentin Mark Anstee, Stefan Neubauer, Patrick M Bossuyt, Michael Pavlides, the LITMUS Investigators

ABSTRACT
Objective Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatty liver disease. The aims of this study were to evaluate the individual diagnostic performance of liver stiffness measurement by vibration controlled transient elastography (LSM-VCTE), Fibrosis-4 Index (FIB-4) and NAFLD (non-alcoholic fatty liver disease) Fibrosis Score (NFS) and to derive diagnostic strategies that could reduce the need for liver biopsies.

Design Individual patient data meta-analysis of studies evaluating LSM-VCTE against liver histology was conducted. FIB-4 and NFS were computed where possible. Sensitivity, specificity and area under the receiver operating curve (AUROC) were calculated.

Results Data were included from 37 primary studies (n=5735; 45% women; median age: 54 years; median body mass index: 30 kg/m²; 33% had type 2 diabetes; 30% had advanced fibrosis). AUROCs of individual LSM-VCTE, FIB-4 and NFS for advanced fibrosis were 0.85, 0.76 and 0.73. Sequential combination of FIB-4 cut-offs (<1.3; ≥2.67) followed by LSM cut-offs (<8.0; ≥10.0 kPa) to rule-in or rule-out advanced fibrosis had sensitivity and specificity (95% CI) of 66% (63–68) and 86% (84–87) with 33% needing a biopsy to establish a final diagnosis. FIB-4 cut-offs (<1.3; ≥3.48) followed by LSM cut-offs (<8.0; ≥20.0 kPa) to rule out advanced fibrosis or rule in cirrhosis had a sensitivity of 38% (37–39) and specificity of 90% (89–91) with 19% needing biopsy.

What is already known on this subject?
- Patients with non-alcoholic fatty liver disease (NAFLD) and advanced fibrosis (F3–4) are at risk of disease progression and adverse clinical outcomes.
- Non-invasive tests with predefined cut-offs are used as screening biomarkers to identify those at low risk of advanced fibrosis who can be safely managed in primary care.
- Liver biopsy is still needed in secondary care to further identify those with cirrhosis who would benefit from surveillance for hepatocellular cancer and screening for oesophageal varices.

Conclusion Sequential combinations of markers with a lower cut-off to rule-out advanced fibrosis and a higher cut-off to rule-in cirrhosis can reduce the need for liver biopsies.

INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome with high prevalence worldwide. Most patients remain asymptomatic for long periods of time (years/decades) with slowly progressive disease, but
patients at high risk of advanced fibrosis. Patients with indeterminate results in both tiers of testing would need a liver biopsy for risk stratification. The main value of these approaches lies in their high negative predictive value to rule out patients with low risk of advanced fibrosis who can be safely managed in primary care.

Despite the increasing evidence to support these approaches, some aspects of their application require further clarifications. First, there is no consensus on which NIT thresholds to use for this purpose. For example, FIB-4 upper cut-offs of 3.25\(^\text{11}\) and 2.67\(^\text{12}\) have been described, while other investigators omit the FIB-4 upper cut-off altogether.\(^\text{13}\) There is also some uncertainty about the performance of NITs in specific patient subgroups, such as those with diabetes or obesity. Furthermore, for patients who are ruled in as being at high risk of advanced fibrosis (F3–4), liver biopsy is often needed to identify those with cirrhosis who would need surveillance for HCC.\(^\text{14}\) Developing approaches that can minimise the need for liver biopsy in secondary care is therefore an area of unmet need.

To address these problems, we conducted an individual patient data meta-analysis (IPDMA) with three main aims: (1) to evaluate the performance of LSM-VCTE and compare it to the performance of FIB-4 and NFS as screening tests to rule out advanced fibrosis; (2) to evaluate NIT combination strategies to minimise the number of cases that would need a liver biopsy in secondary care; (3) to explore factors that influence diagnostic accuracy.

**METHODS**

This IPDMA was reported in accordance with the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses-IPD Statement\(^\text{15}\) and was registered as PROSPERO CRD42019157661.

**Criteria for considering studies for the IPD meta-analysis**

**Patients**

Studies reporting data on adults (≥18 years) with NAFLD and paired liver histology and LSM-VCTE were eligible. When studies reported study groups of participants with unsel ected aetiologies, only IPD of those with NAFLD were sought.

**Index tests**

The index test of main interest was LSM-VCTE performed with FibroScan (Echosens, France). Results for serum-based biomarkers NSF,\(^\text{16}\) FIB-4,\(^\text{17}\) aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio,\(^\text{18}\) and AST-to-platelet ratio index (APRI)\(^\text{19}\) were also computed where data were available. Online supplemental table 1 summarises the definition of NITs considered in this IPDMA.

Universally accepted cut-offs for diagnosing different groups of fibrosis stages do not exist (several suggested cut-offs are presented in online supplemental table 2). For LSM-VCTE, <7.9 kPa and ≥9.6 kPa are the most used for respectively ruling out and in, advanced fibrosis.\(^\text{20}\)

**Reference standard**

Only studies reporting histological classification of liver fibrosis based on the non-alcoholic steatohepatitis Clinical Research Network (NASH CRN) staging system were considered.\(^\text{21}\)

**Target conditions**

Advanced fibrosis (F3–4) and cirrhosis (F4) were the target conditions of interest. To fulfil the aims of the study, cut-offs...
were selected to rule out or rule in advanced fibrosis, and to rule out advanced fibrosis or rule in cirrhosis.

Study design
All study designs were considered if they were reporting on patients with NAFLD undergoing both liver biopsy and LSM-VCTE within 6 months. No language restrictions were applied.

Establishing collaborations
Authors of eligible studies were contacted by email and reminders were sent if a response was not received within 2 weeks. Only data from studies that received ethical approval were used. Additional ethical approval was not sought for the meta-analysis as only anonymised data were provided.

Data verification
Range checks of measurement values provided for individual patients were carried out and authors were asked to provide clarifications where necessary. Missing data were queried until received or confirmed as unavailable. Missing data were handled in the analysis by pairwise deletion.

LSM-VCTE with median stiffness ≥7.1 kPa and IQR-to-median LSM ratio >30% were considered unreliable. These were included in the main analysis and were later compared in a subgroup analysis to reliable measurements, to assess whether they can be reliably used to diagnose advanced fibrosis.

Authors were provided with a template table of required data (online supplemental table 3) and were asked to deduplicate data were possible. We also checked for duplicate entries and where identified these were removed.

Data analysis
Quality and bias assessment
The quality of studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2).

IPD meta-analysis
The original data sets were merged, a study identification variable was added, and descriptive statistical analysis of the data sets was conducted. Dichotomous variables are displayed as percentages. Continuous variables are reported as means with SD, or medians with IQRs according to the distribution of the data.

Analyses were done per protocol, as we did not have information on failed LSM-VCTE. The main analysis was conducted to maximise data for each NIT. For a valid comparison of the performance of NITs, a separate analysis was conducted in the subgroup of patients where all three of VCTE, FIB-4 and NFS were available in each participant.

To fulfill the aim of developing testing strategies that reduce the number of patients in need of a liver biopsy, lower cut-offs for ruling out advanced fibrosis and upper cut-offs for ruling in cirrhosis were used. The rationale for this approach is illustrated in online supplemental figure 1. The upper cut-offs for identifying cirrhosis were chosen at 95% and 98% specificity in a derivation set and tested in a validation set. Derivation and validation sets were obtained by random sampling from the IPD study group in a 3:2 ratio. These upper cut-offs were combined with lower cut-offs from the literature for ruling out advanced fibrosis and the algorithm was tested in the whole IPD study group. For ease of reference, we also examined the cut-offs of 8 kPa and 10 kPa (corresponding to the most common VCTE cut-offs in the literature of 7.9 kPa and 9.6 kPa rounded to the nearest integer) and also rounded our cirrhosis cut-offs to the nearest integer to facilitate application in clinical practice.

Only test-positive and test-negative patients were included in the calculation of diagnostic performance indices, and patients in the indeterminate group were excluded from calculations.

Subgroup analysis was performed according to biopsy length (<20 mm, ≥20 mm), number of portal tracts in biopsy samples (<11, ≥11), biopsy quality (intermediate: 10 mm ≤ length < 20 mm; high: length ≥ 20 mm and ≥11 tracts), age (four quartiles), sex, body mass index (BMI; BMI <25 kg/m², 25 kg/m² ≤ BMI <30 kg/m², BMI ≥30 kg/m²), presence of type 2 diabetes mellitus (T2DM), continent of provenance (Europe, Asia), probes used (M, XL), reliability criteria for LSM-VCTE (reliable (median LSM <7.1 kPa or median LSM ≥7.1 kPa and IQR/median LSM <0.30) vs unreliable (median LSM ≥7.1 kPa and IQR/median LSM ≥0.30)) ; reliable (IQR/median LSM <0.30) vs unreliable (IQR/median LSM ≥0.30), and aminotransferase levels (ALT or AST<40, 40≤ALT or AST<100, ALT or AST≥100; ALT<40 and AST<40, ALT≥40 or AST≥40).

All statistical analyses were performed using R (V1.2.1335, R Foundation for Statistical Computing, Vienna, Austria) with the pROC package, 95% CIs were calculated using 500 stratified bootstrap replicates using the boot package.

VCTE probe types
The analysis to account for probe type is described in the online supplemental materials.

Patient and public involvement
Patients and the public were not involved in the conduct of this study as there was no direct patient participation in the study.

RESULTS
Search process and data collection
Ten thousand three hundred ninety-two articles were identified in a search performed for a larger systematic review evaluating the diagnostic performance of LSM-VCTE and other index tests for the staging of fibrosis and diagnosis of NASH in adult patients with NAFLD. After removing duplicates, and screening titles, abstracts, and full texts, 59 studies examining VCTE were identified. The authors of 37 studies shared useable data (figure 1). Authors of more than one study supplied data in a single dataset and, overall, we received 30 data sets including data from 6571 patients. After removing duplicates (n=628) and patients with...
missing biopsy (n=14) or LSM-VCTE (n=194) data, the final dataset consisted of 5735 unique patients.

Study and population characteristics
The characteristics of the 30 data sets are summarised in table 1. Studies were conducted in Europe (67%), Asia (40%) and Australia (3%). Data availability is shown in online supplemental table 3. FIB-4 and NFS were determined in 5393 (94%) and 3248 (57%) cases, respectively. Median age was 54 years, 2570 (45%) patients were women, 33% had diabetes and 43% had BMI ≥30 kg/m². Overall, 30% had advanced fibrosis and 11% had cirrhosis. Details of the IPD study group are included in table 1, and online supplemental tables 4 and 5.

Study quality
The methodological quality of the studies assessed with the QUADAS-2 tool is summarised in online supplemental figures 2 and 3. Only one study had low risk of bias or low applicability concerns in all QUADAS-2 domains.28 The flow and timing domain were judged to have high risk or unclear risk of bias in 65% of studies, as these either excluded technical failures from their final diagnostic performance analysis or did not report them.

Validating the diagnostic performance of LSM by VCTE and serum-based tests for detecting advanced fibrosis
LSM-VCTE, FIB-4, NFS, APRI and AST/ALT had corresponding AUROCs of 0.85, 0.76, 0.73, 0.70, 0.64 for identifying advanced fibrosis (table 3), and 0.90, 0.80, 0.78, 0.72, 0.69 for the identification of cirrhosis (online supplemental table 6). LSM-VCTE performed significantly better (p<10⁻¹⁵) in detecting both advanced fibrosis and cirrhosis than all serum-based tests. This relationship was preserved when performing a head-to-head comparison of LSM-VCTE, FIB-4 and NFS in the same group of patients (online supplemental tables 7 and 8).

When considering cut-offs from the literature, we evaluated lower and higher cut-offs separately. For any given test, as would be expected, low thresholds yielded higher sensitivity and high thresholds were associated with higher specificity (online supplemental table 9). Indicative PPV and NPV are also provided for the range of prevalences (5%–50%) reported in the primary studies (online supplemental tables 10–14).

APRI and AST/ALT ratio had only modest diagnostic performance for advanced fibrosis (AUROC ≤0.70, table 3), and were therefore not considered further.

None of the thresholds regarded in isolation resulted in both a high sensitivity (≥80%) and high specificity (≥80%) (figure 2, table 3, online supplemental tables 9 and 15, and online supplemental figure 4). Therefore, we explored the use of a lower and an upper cut-off. LSM-VCTE literature cut-offs performed well in only two cases (<7.1 kPa and ≥14.1 kPa: 83% sensitivity, 90% specificity; and <7.9 kPa and ≥9.6 kPa: 84% sensitivity, 78% specificity), while for other LSM-VCTE, NFS and FIB-4 thresholds a high specificity was observed (FIB-4: 91% for <1.3 and ≥2.67, 95% for <1.3, ≥3.25) but sensitivity was <60% (table 4). In addition, the proportion of indeterminate cases was >30% for serum-based NTIs. Threshold pairs derived from the IPD study group did not reduce the proportion of misclassified and indeterminate patients seen with literature-based threshold pairs (table 4).

We further evaluated the performance of LSM-VCTE, FIB-4 and NFS to diagnose advanced fibrosis in sequential combinations of serum-based NTIs and LSM-VCTE. When selecting threshold combinations for FIB-4 and NFS available in the literature (<1.3 & ≥2.67,<1.3 & ≥3.25 for FIB-4; <1.455 & ≥0.676 for NFS) and pairing them with the best threshold pair for LSM-VCTE (<7.9 kPa & ≥9.6 kPa, identified as the one with highest sensitivity and lowest indeterminate proportion), the proportion of patients in the indeterminate group was 5%. While both the FIB-4+LSM VCTE and NFS+LSM VCTE sequential combinations had specificity >80%, their sensitivity was ≤80% (table 5). A better sensitivity was reached by using thresholds derived from the IPD study group (<0.88 & ≥2.31 for FIB-4; <−2.55 & ≥0.28 for NFS), but the proportion of indeterminate cases was near 20% in those cases and the proportions of patients needing LSM-VCTE was also larger than when using literature cut-offs (table 5).

Algorithms to minimise the need for liver biopsy
In the derivation set, the cut-offs for 95% and 98% specificity for the diagnosis of cirrhosis were respectively 20.4 kPa and 27.6 kPa for LSM-VCTE, 3.48 and 4.63 for FIB-4 and 1.01 and 1.57 for NFS. These cut-offs performed similarly in the validation set (online supplemental tables 16 and 17).
Table 1  Details of individual patient data included in this meta-analysis

| Data set ID | Country | Study design | Number of participants (n) | Age (year) | BMI (kg/m²) | WC (cm) | M/F | Recruitment interval | Hardware used | Probe used |
|-------------|---------|--------------|----------------------------|------------|-------------|---------|-----|----------------------|--------------|------------|
| Agrawal et al64 | UK | MC, P, CS | 25 | 47.8 (19–70) | 27.7 (15.8–35.7) | 95.4 (39–120) | 18/7 | 2009–2012 | – | M |
| Aykut et al65 | Turkey | SC, P, CS | 88 | 46.0 (24–62) | 30.3 (18.3–41.8) | 101.5 (70–143) | 50/38 | – | FibroScan 502 Touch | M |
| Boursier et al66,67 | France | MC, P, CS | 1063 | 56.1 (18–83) | 31.6 (16.3–55.5) | 108.3 (58–174) | 61/3450 | – | – | M or XL |
| Cassinotto et al54 | France | SC, P, CS | 61 | 55.9 (22–81) | 30.1 (16.7–46.6) | 103.6 (72–125) | 40/21 | 2010–2012 | – | M and XL |
| Cassinotto et al55 | France | MC, P, CS | 286 | 56.6 (18–80) | 32.2 (20.3–51.7) | 109.8 (68–168) | 171/115 | 2011–2015 | – | M and XL |
| Chan et al56 | Malaysia | SC, P, CS | 146 | 50.4 (18–73) | 29.4 (6.9–41.2) | 98.3 (79–127) | 80/66 | 2012–2013 | FibroScan 502 Touch | M and XL |
| Chan et al57 | Malaysia, Hong Kong | MC, P, CS | 153 | 54.0 (24–76) | 29.9 (20.1–44.8) | 98.4 (69–141) | 68/85 | – | FibroScan 502 Touch | M and XL |
| Eddowes et al58,59 | UK | MC, P, CS | 358 | 53.3 (19–77) | 34.2 (19.5–53.2) | 117.2 (65–158) | 206/152 | – | – | M or XL |
| Eddowes et al58,59 | UK | MC, P, CS | 50 | 50.2 (18–73) | 33.6 (23.6–47.8) | 109.4 (89–132) | 28/22 | 2014–2015 | – | M or XL |
| Gaia et al60 | Italy | SC, P, CS | 68 | 46.8 (29–65) | 28.0 (21.2–40.2) | – | 48/20 | 2007–2009 | – | M |
| Garg et al61 | India | SC, P, CS | 76 | 38.2 (20–65) | 45.2 (32.3–73.8) | – | 16/60 | 2014–2016 | FibroScan 502 Touch | XL |
| Karlas et al62 | Germany | SC, P, CS | 41 | 45.7 (28–64) | 47.7 (33.7–60.1) | – | 13/28 | – | FibroScan 502 XL | – |
| Labenz et al63 | Germany | SC, P, CS | 126 | 47.4 (20–73) | 31.6 (23.5–50.4) | – | 72/54 | – | FibroScan 402 | M or XL |
| Lee et al64 | Korea | SC, P, CS | 94 | 55.5 (19–82) | 27.2 (19.1–36.3) | – | 41/53 | 2014–2015 | – | M or XL |
| Lupstor et al65 | Romania | SC, P, CS | 72 | 42.4 (20–69) | 29.7 (21.0–41.5) | 102.4 (65–124) | 51/21 | 2007–2009 | – | M |
| Mahadeva et al66 | Malaysia | SC, P, CS | 131 | 49.9 (23–75) | 28.7 (18.5–41.3) | 93.5 (43–128) | 66/65 | 2009–2010 | – | M |
| Okajima et al67 | Japan | SC, P, CS | 173 | 56.3 (18–81) | 27.2 (16.5–40.3) | – | 84/99 | 2013–2015 | – | M |
| Ooi et al68 | Australia | MC, P, CS | 82 | 44.5 (18–67) | 46.2 (29.1–74.0) | 136.5 (101–192) | 23/59 | 2015–2016 | – | M or XL |
| Pavlides et al69 | UK | SC, P, CS | 70 | 53.5 (25–77) | 34.5 (23.0–57.3) | 112.5 (80–149) | 42/28 | 2011–2015 | – | M or XL |
| Petta et al70,71 | Italy | MC, P&R, CS | 234 | 45.5 (15–78) | 28.2 (15.7–40.7) | 99.4 (69–126) | 16/95 | 2008–2013 | – | M |
| Petta et al72 | France, Hong Kong, Italy | MC, P, CS | 260 | 54.6 (15–87) | 29.4 (16.5–46.6) | 100.9 (74–148) | 122/138 | – | – | M |
| Petta et al73 | Italy | MC, P, CS | 474 | 45.5 (19–77) | 29.2 (15.2–49.5) | 99.6 (47–164) | 275/199 | – | – | M |
| Seki et al74 | Japan | SC, P, CS | 181 | 57.7 (16–82) | 27.1 (16.9–38.1) | 95.1 (71–117) | 91/90 | 2013–2015 | – | M |
| Shen et al75 | China | MC, P, CS | 101 | 59.0 (16–60) | 27.0 (20.1–37.3) | 92.9 (75–120) | 74/27 | 2012–2014 | FibroScan 502 M | – |
| Staufer76 | Austria | MC, P, CS | 186 | 49.6 (19–83) | 32.5 (19.0–56.9) | – | 106/80 | 2011–2016 | FibroScan 502 Touch | M or XL |
| Wong et al76–79 | Hong Kong, France | MC, P, CS | 464 | 53.8 (20–83) | 30.5 (17.3–48.0) | 102.0 (71–148) | 201/263 | 2009–2017 | – | M and XL |
| Wong et al80 | Hong Kong, France | MC, P, CS | 273 | 51.6 (21–77) | 28.8 (16.5–54.0) | 96.2 (65–144) | 147/126 | 2003–2009 | – | M |
| Yoneda et al81 | Japan | MC, P, CS | 97 | 52.1 (19–76) | 26.5 (17.9–38.5) | – | 41/56 | <2008 | – | M |
| Younes et al82 | Italy | SC, P, CS | 289 | 44.8 (15–78) | 28.8 (17.5–41.7) | 98.9 (47–128) | 199/90 | – | – | M |
| Ziol et al83 | France | SC, P, CS | 13 | 49.3 (39–60) | 29.4 (23.8–34.6) | – | 10/3 | 2003–2005 | – | M |

– Data not available; BMI, body mass index; CC, case-control; CS, cross-sectional; F, females; M, males; MC, multicentre; P, prospective; R, retrospective; SC, single-centre; WC, waist circumference.

Algorithms combining FIB-4 (lower cut-off of 1.3 as described in the literature and upper cut-offs of 3.48 and 4.63 as described above) and LSM by VCTE (lower cut-off rounded to 8.0 kPa and upper cut-offs rounded to 20.0 kPa and 28.0 kPa, as described above) were then compared with the traditional way of applying these tests, also with rounded cut-offs for LSM by VCTE (8 kPa and 10 kPa) (figure 3). This approach increased the number of patients requiring a LSM.
Subgroup and sensitivity analyses

In subgroup analysis for the diagnosis of advanced fibrosis (online supplemental table 19), NITs performed better in patients with lower BMI (AUROCs LSM-VCTE: 0.91, p<0.005; FIB-4: 0.81, p<0.001; NFS: 0.76, p<0.025), without T2DM (LSM-VCTE: 0.87, p<10^{-6}; FIB-4: 0.77, p<0.01), and with biopsies shorter than 20 mm (LSM-VCTE: 0.87, p<0.005; FIB-4: 0.80, p<0.001; NFS: 0.79, p<0.05), or with fewer than 11 portal tracts (LSM-VCTE: 0.86, p=0.01; FIB-4: 0.79, p=0.04; NFS: 0.78, p<0.005). Diagnostic performance was also lower in patients in the youngest age quartile (<43 years, AUROC: 0.58, p<0.001) and in women (AUROC: 0.71, p=0.03) for NFS, while in men the performance did not change from 34% to 40% and 44% but decreased the number of patients needing liver biopsy (from 33% to 19% and 24% when using the 95% and 98% specificity cut-offs, respectively) (online supplemental table 18 and figure 3).

Table 3  Diagnostic performance of non-invasive tests for advanced fibrosis (F3–F4)

| Test | Advanced fibrosis (%) | AUROC | YI | 90% Se | 90% Sp | Threshold | Sensitivity, % | Specificity, % | Misclassified, % |
|------|------------------------|-------|----|--------|--------|-----------|--------------|---------------|-----------------|
| LSM  | 30                     | 0.73  | 0.71 | 0.69   | 0.80   | 12.1      | 77 (75–79)   | 76 (80–91)    | 22 (22–23)      |
| FIB-4| 30                     | 0.76  | 0.74 | 0.77   | 0.88   | 12.1      | 77 (75–79)   | 76 (80–91)    | 22 (22–23)      |
| NFS  | 29                     | 0.73  | 0.71 | 0.75   | 0.80   | 12.1      | 77 (75–79)   | 76 (80–91)    | 22 (22–23)      |
| APRI | 30                     | 0.73  | 0.71 | 0.75   | 0.80   | 12.1      | 77 (75–79)   | 76 (80–91)    | 22 (22–23)      |
| AST/ALT | 30                 | 0.73  | 0.71 | 0.75   | 0.80   | 12.1      | 77 (75–79)   | 76 (80–91)    | 22 (22–23)      |

For each non-invasive test thresholds were selected according to Youden’s index (YI), and fixed at 90% sensitivity (90% Se) and 90% specificity (90% Sp). 95% CIs were estimated with 500 bootstrap replicates.

ALT, alanine aminotransferase; APRI, AST-to-platelet ratio index; AST, aspartate aminotransferase; FIB-4, Fibrosis-4 Index; LSM, liver stiffness measurement; NFS, NAFLD (non-alcoholic fatty liver disease) Fibrosis Score; VCTE, vibration controlled transient elastography.
performed better in patients with AST<40 (AUROC: 0.76), than in patients with AST≥100 (AUROC: 0.65, p<0.01). FIB-4 performed better in patients with at least one abnormal aminotransferase measurement (AUROC: 0.72, p=0.014).

For cirrhosis, the trends were similar, except that for the diagnosis of cirrhosis, LSM by VCTE performed better in the youngest age group (AUROC: 0.97, p<10\(^{-4}\)) and NIT diagnostic performance was independent of aminotransferase levels (online supplemental table 20).

The diagnostic performance of LSM-VCTE was significantly lower in patients with unreliable LSMS (p<10\(^{-4}\); both for advanced fibrosis and cirrhosis) when applying the Boursier-criteria, but not when only considering IQR/median LSM <0.30. The proportion of unreliable results was 12% both in the advanced fibrosis and cirrhosis groups (online supplemental table 21).

There was no difference in the diagnostic performance of LSM-VCTE between the M and XL probes in the subgroup of patients who had undergone LSM by both probes (online supplemental table 22).

In a sensitivity analysis of patients with LSM matched to BMI (only M probe measurements if BMI <30 kg/m\(^2\) and only XL probe measurements if BMI ≥30 kg/m\(^2\)), there was no significant difference between the diagnostic performance of LSM-VCTE when comparing to the entire IPD study group (online supplemental table 23).

Figure 2  Distribution of sensitivities and specificities over the possible threshold ranges for liver stiffness measurement (LSM) by vibration controlled transient elastography (VCTE) (A), Fibrosis-4 Index (FIB-4) (B) and NAFLD (non-alcoholic fatty liver disease) Fibrosis Score (NFS) (C) when considering the diagnosis of advanced fibrosis. Insets show the distribution of cut-offs identified from the literature. Horizontal dashed lines are representing the minimum acceptable criteria for considering a test as having high sensitivity (≥80%) and high specificity (≥80%).
### DISCUSSION

Through an extensive collaboration network with authors of primary studies, we were able to collect the largest dataset of its kind ever to be reported on. This includes a diverse set of study groups from Europe, Asia, and Australia, 30% of whom had advanced fibrosis. We believe that our findings are therefore relevant for patients typical of secondary care in these territories and may be applied in the development of new strategies or in the consolidation of existing practices in evaluating patients for referral to secondary care.

A few studies evaluated the diagnostic performance of LSM-VCTE and other NITs, but most report on fewer than 500 patients. One similarly large study reported on patients screened for inclusion in clinical trials, where the prevalence of advanced fibrosis was 71%,\(^\text{29}\) making it difficult to make generalisations about its applicability in routine practice or compare its results to ours. A smaller study with 1073 patients with NAFLD of whom 29% had advanced fibrosis\(^\text{30}\) examined the diagnostic performance of LSM by VCTE. The authors of that study reported AUC and specificity values similar to our findings, however they reported increased sensitivity. Other smaller studies reported similar prevalence of advanced fibrosis and similar AUROCs for LSM-VCTE.\(^\text{31–34}\)

Overall, the diagnostic performance of LSM-VCTE for advanced fibrosis was good (AUROC=0.85), while that of FIB-4 and NFS in the same group was moderate (AUROC=0.76 for FIB-4, AUROC=0.73 for NFS). None of the studied NITs had both sufficiently high sensitivity and specificity (≥80%) when used with single cut-offs. Diagnostic performance was higher for detecting cirrhosis, as reported in previous studies.\(^\text{31–35}\)\(^\text{36}\) LSM-VCTE had the highest sensitivity and specificity, both in the case of a single cut-off (9.1 kPa obtained by maximising the Youden index; 77% and 78%) and for two cut-offs (<7.4 kPa & ≥12.1 kPa; 84% and 87%). Of the LSM-VCTE cut-off pairs tested, <7.1 kPa and ≥14.1 kPa, first published by Eddowes et al.,\(^\text{31}\) performed well for advanced fibrosis, with sensitivity of 83% and specificity of 90%, but with a proportion of 39% of patients ending up with an indeterminate result, similar to 41% indeterminate patients reported in the original paper.\(^\text{32}\)

LSM-VCTE thresholds identified in our study group (<9.1 kPa; <7.4 kPa & ≥12.1 kPa) were similar to thresholds reported in the literature (<9.9 kPa; <7.1 kPa & ≥14.1 kPa, <7.9 kPa & ≥9.6 kPa). However, thresholds for FIB-4 (<1.44; <0.88 & ≥2.31) and NFS (<−1.39; <−2.55 & ≥0.28) defined in our IPD study group spanned a wider range than those reported in the literature (<1.3 & ≥2.67 or <1.3 & ≥3.25 for FIB-4; <−1.455 & ≥0.676 for NFS).

Our findings are in line with the existing literature suggesting that sequential combinations of NITs increase sensitivity and specificity.\(^\text{29}\) Additionally, we have found NFS+LSM VCTE and FIB-4+LSM VCTE combinations to have similar sensitivity and specificity as recently reported by Boursier et al.\(^\text{37}\) Such combined testing strategies can reduce the number of indeterminate cases and reduce the costs associated with liver biopsies.

Furthermore, we propose an approach that could minimise the need for liver biopsies further, by using upper cut-offs with 95% and 98% specificity for the identification of cirrhosis. The rationale for this approach is explained in the online supplemental discussion. When using the 95% specificity cut-off, the proportion of patients needing liver biopsy decreases from 33% to 19% (figure 3). However, in this approach, 345 of 656 patients ‘ruled-in’ as having cirrhosis do not have histologically diagnosed cirrhosis. While this may seem like a high proportion...
of patients with false positive results, this must be interpreted in the light of two factors. First, the limitations of liver biopsy could mean that these patients are falsely classified as not having cirrhosis histologically. Furthermore, patients without cirrhosis on histology and with high NIT values could have equivalent risks as patients with cirrhosis on histology. For example, it is known from the hepatitis C literature that patients without cirrhosis on liver biopsy but with a high FIB-4 (>3.25) still had a significant risk of developing HCC after hepatitis C treatment, demonstrating that NITs can have added benefit beyond the histological diagnosis of cirrhosis alone. The rate of false positive results for cirrhosis can be decreased by choosing cut-offs with higher specificity, but this will come at the expense of doing more biopsies. Despite this encouraging result, this is an area where more information is needed, particularly longitudinal data comparing the prognostic value of LSM-VCTE and other NITs against histology, and ultimately, the cost effectiveness of the various cut-offs would need to be evaluated.

Surprisingly, subgroup analyses showed that the diagnostic accuracy of NITs was better in cases with poor biopsy quality. This finding is difficult to explain but a similar observation was reported previously in a large group of patients screened for clinical trials. The use of local biopsy reports as reference standard and the well-known observer-dependent variability of biopsy interpretation, even among expert pathologists, are factors that may have contributed to our finding. Spectrum bias was excluded as a source of this finding due to a near-identical proportion of patients in both the advanced fibrosis and cirrhosis group having short biopsies (online supplemental table 5).

Subgroup analysis showed better diagnostic performance of NITs in patients with lower BMI, and patients without diabetes, in keeping with other studies. This effect is likely to be primarily driven by BMI as there is thought to be a causal association between BMI and T2DM. NIT performance was impacted by age, with all NITs performing worse in the younger quartile of our study group for advanced fibrosis, but the trend was reversed for cirrhosis where NITs performed better in those younger than 43 years of age. The age dependence of FIB-4 and NFS is expected, as age is one of the parameters included in the algorithms, and has indeed been previously described. It is, however, difficult to explain why performance of NITs is better in the younger age group for the diagnosis of cirrhosis.

Our study has several strengths, including the large size of the IPD study group and composition with prevalence of advanced fibrosis of 30%, which makes it relevant to routine practice. Furthermore, the proportion of unreliable VCTE measurements in our study was 12%, in keeping with the literature. However, we acknowledge some limitations. We did not have any data from the USA and very few studies from Australia, so the results could not be globally applicable, due to differences in BMI across study populations. In addition, due to the nature of our study, we had to use the locally provided histology results possibly introducing bias. Furthermore, we covered a large chronological period, during which LSM-VCTE application underwent significant changes, initially with the introduction of the XL probe, followed by the advice to measure skin-to-capsule distance (SCD) and the introduction of the Automatic Probe Selection tool. There was therefore some heterogeneity in the performance of LSM-VCTE, with early studies using only the M probe to assess all patients, while only a subset of studies assessed SCD to guide probe selection. Furthermore, one third of the included studies was carried out in France, as the technology used for LSM by VCTE originates from there. Lastly, our data confirm that LSM-VCTE had superior accuracy to serum-based tests, and this is independent of probe type, sex, ALT, AST, and participants’ continent of origin. There was, however, some dependence on the presence of T2DM, BMI and for the detection of cirrhosis, and we did not check for subgroup-specific cut-offs, but these should be explored in future studies.

Our study examined some of the most widely available NITs. While it cannot be considered exhaustive, it can be regarded as the benchmark against which newer NITs can be tested. This is particularly important as new tests are continuously being developed (FibroTest-FibroSURE, ActiT est, ELF). Furthermore, newer tests are also needed for patients with ‘at risk’ NASH (NASH+F2–3) who would be candidates for clinical trials or treatments, once approved therapies become available (FAST score, NIS4, cTAG). In conclusion, our study provides further validation of the use of sequential combination of FIB-4 and LSM-VCTE to rule out patients with NAFLD and advanced fibrosis who can be managed in primary care. We have shown how the use of lower cut-offs to rule in cirrhosis in combination with lower cut-offs to...
rule out advanced fibrosis can lead to a reduction in the number of patients who would need to undergo liver biopsy.

Author affiliations
1 Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
2 Department of Epidemiology and Data Science, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
3 Translational Gastroenterology Unit, University of Oxford, Oxford, UK
4 NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust and the University of Oxford, Oxford, UK
5 Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
6 Laboratoire HIFIH, UPRES EA 3839, SFR ICAT 4208, Universite d’Angers, Angers, Pays de la Loire, France
7 Service d’Hepato-Gastroenterologie et Oncologie Digestive, Centre Hospitalier Universitaire d’Angers, Angers, Pays de la Loire, France
8 Echosens SA, Paris, Ile-de-France, France

Figure 3  Sankey diagrams showing the distribution of patients in true positive, true negative, false positive, false negative and indeterminate groups for a sequential combination of Fibrosis-4 Index (FIB-4) and liver stiffness measurement (LSM) by vibration controlled transient elastography (VCTE) when using different thresholds for each testing tier. A lower threshold was used to rule out patients without advanced fibrosis and an upper threshold ruled in patients with advanced fibrosis when applying both tests (A). In an alternative model, a lower threshold was used to rule out patients without advanced fibrosis, but the upper threshold ruled in only patients with cirrhosis (B, C). Two different pairs of thresholds were chosen for this hybrid strategy: the lower cut-off for both FIB-4 and LSM by VCTE were determined from the literature; upper cut-offs were both determined as corresponding to 95% specificity in detecting cirrhosis (B) or both corresponding to 98% specificity in detecting cirrhosis (C). In the application of the algorithm described in (A) 33% of patients would need to have a liver biopsy for the diagnosis of cirrhosis (those in the indeterminate group to rule out advanced fibrosis and those in the rule in group to identify cirrhosis). With the application of an upper cut-off to rule in cirrhosis without the need of biopsy, only patients in the indeterminate group need to have a biopsy. The latter strategy results in fewer patients undergoing biopsy (18% and 24% depending on the threshold used). Tables next to each panel contain the number and proportion of patients in each of the true positive (TP), true negative (TN), false positive (FP) and false negative (FN) groups for FIB-4 and LSM by VCTE.
Hepatology

Manuel Romero-Gómez, Emilio Gómez-González, Javier Ampuero, Javier Castell, Rocío Gallego-Durán, Isabel Fernández, Rocío Monterro-Vallejo (Servicio Andaluz de Salud, Seville); Morten Karsdal, Elisabeth Erhardtsen, Daniel Rasmussen, Diana Julie Leeming, Mette Juul Fisker, Antonia Sinis, Kishwar Musa (Nordic Bioscience); Fay Betou, Estelle Sandt, Manuela Tonini (Integrated Biobank of Luxembourg); Elsa L. Anguianes, Chiara Scaglioni, Elisacid Di Martino, Elisabetta Senatore, Francesca Galtellidi (CNR), Gianluca Svegliati (UNIPM) (University of Turin); Jérôme Bourjot (University Hospital of Angers); Sven Francque; Luisa Vonghia (Antwerp University Hospital); Mattias Ekstedt, Strygios Kehagias (Linköping University); Hannele Yki-Jarvinen, Kimmo Porthan (University of Helsinki); Saskia van Mil (UMC Utrecht); George Papageorgiou (National & Kapodistrian University of Athens); Réhénien de Broin, Nathalie Pougnet, Christel Leger, Franck Fournier, Sarah-Elize Coqueret, Arnaud Dufour, Alexandre Héron, Laura Chomka, Pauline Boudin, Fabrice Sibille, Thomas Sastre, Claire Dejouze, Myriam Bakar (Inserm); Manuel Fuentes-Marchart, Iman Fakhraddini, Elodie Sandoz, catharyn Maccabee, Carola Bichler, Noémie Valson, Mélanie Verlet, Sylvain Heremans, Jean-Pierre Empan, David Mieusset, Fabrice Collet, Jean-Claude Debord, Karine Tremollieres, Elodie Giroix, Maxime Roquebert; Cédric Pech (AP-HP); Taryn Boyer, Sanjiv K. Trivedi, Gregord Roennekamp, Karim Douay, Maria Almeida, Olivier Guével, Oralvo Cousin,URRENCY study Investigators: Quentin Anstee, Ann Daly, Katherine Johnson, Olivier Govaere, Simon Cockell, Dina Tiniakos, Alain Chastanet, Cédric Pech (AP-HP); Taryn Boyer, Sanjiv K. Trivedi, Gregord Roennekamp, Karim Douay, Maria Almeida, Olivier Guével, Oralvo Cousin, Currency study Investigators: Quentin Anstee, Ann Daly, Katherine Johnson, Olivier Govaere, Simon Cockell, Dina Tiniakos, Alain Chastanet, Cédric Pech (AP-HP); Taryn Boyer, Sanjiv K. Trivedi, Gregord Roennekamp, Karim Douay, Maria Almeida, Olivier Guével, Oralvo Cousin, Currency study Investigators: Quentin Anstee, Ann Daly, Katherine Johnson, Olivier Govaere, Simon Cockell, Dina Tiniakos, Alain Chastanet, Cédric Pech (AP-HP); Taryn Boyer, Sanjiv K. Trivedi, Gregord Roennekamp, Karim Douay, Maria Almeida, Olivier Guével, Oralvo Cousin, Currency study Investigators: Quentin Anstee, Ann Daly, Katherine Johnson, Olivier Govaere, Simon Cockell, Dina Tiniakos, Alain Chastanet, Cédric Pech (AP-HP); Taryn Boyer, Sanjiv K. Trivedi, Gregord Roennekamp, Karim Douay, Maria Almeida, Olivier Guével, Oralvo Cousin, Currency study Investigators: Quentin Anstee, Ann Daly, Katherine Johnson, Olivier Govaere, Simon Cockell, Dina Tiniakos, Alain Chastanet, Cédric Pech (AP-HP); Taryn Boyer, Sanjiv K. Trivedi, Gregord Roennekamp, Karim Douay, Maria Almeida, Olivier Guével, Oralvo Cousin, Currency study Investigators: Quentin Anstee, Ann Daly, Katherine Johnson, Olivier Govaere, Simon Cockell, Dina Tiniakos, Alain Chastanet, Cédric Pech (AP-HP); Taryn Boyer, Sanjiv K. Trivedi, Gregord Roennekamp, Karim Douay, Maria Almeida, Olivier Guével, Oralvo Cousin, Currency study Investigators: Quentin Anstee, Ann Daly, Katherine Johnson, Olivier Govaere, Simon Cockell, Dina Tiniakos, Alain Chastanet, Cédric Pech (AP-HP); Taryn Boyer, Sanjiv K. Trivedi, Gregord Roennekamp, Karim Douay, Maria Almeida, Olivier Guével, Oralvo Cousin, Currency study Investigators: Quentin Anstee, Ann Daly, Katherine Johnson, Olivier Govaere, Simon Cockell, Dina Tiniakos, Alain Chastanet, Cédric Pech (AP-HP); Taryn Boyer, Sanjiv K. Trivedi, Gregord Roennekamp, Karim Douay, Maria Almeida, Olivier Guével, Oralvo Cousin, Currency study Investigators: Quentin Anstee, Ann Daly, Katherine Johnson, Olivier Govaere, Simon Cockell, Dina Tiniakos, Alain Chastanet, Cédric Pech (AP-HP); Taryn Boyer, Sanjiv K. Trivedi, Gregord Roennekamp, Karim Douay, Maria Almeida, Olivier Guével, Oralvo Cousin, Currency study Investigators: Quentin Anstee, Ann Daly, Katherine Johnson, Olivier Govaere, Simon Cockell, Dina Tiniakos, Alain Chastanet, Cédric Pech (AP-HP); Taryn Boyer, Sanjiv K. Trivedi, Gregord Roennekam...
REFERENCES

1. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:1–20.

2. Looma R, Wong R, Frayze J, et al. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. Aliment Pharmacol Ther 2020;51:1149–59.

3. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts 2016;9:965–90.

4. Thampanitchawong P, Piravatsathit T. Liver biopsy complications and risk factors. World J Gastroenterol 1999;5:301–4.

5. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1998–906.

6. Standish RA, Cholongias E, Dillon A, et al. An appraisal of the histopathological assessment of liver biopsy. Gut 2006;55:506–11.

7. Dawson BA, Harrison SA, Cotter G, et al. Improved noninvasive prediction of liver fibrosis in patients with nonalcoholic fatty liver disease. Gut 2020;70:983–91.

8. Dawson BA, Harrison SA, Cotter G, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol 2020;73:1322–32.

9. Eskstedt M, Fransen-Le Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865–73.

10. Eskstedt M, Hagström H, Nasi P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547–54.

11. Taylor RS, Taylor RJ, Baylis S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology 2020;158:e12:1611–25.

12. Srivastava A, Gailer R, Tanwar S, et al. Non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease. J Hepatol 2019;71:371–8.

13. Moolla A, Motchetch K, Marjot T, et al. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardiac metabolic health. Frontline Gastroenterol 2019;10:337–46.

14. Davydov T, Tandon P, Al-Karaghouthi M, et al. Impact of Implementing a “FiB-1 First” Strategy on a Pathway for Patients With NAFLD Referred From Primary Care. Hepatol Commun 2019;3:1322–33.

15. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)/Marchesini G, Day CP, Dufour JF. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388–402.

16. Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement. JAMA Netw Open 2019;2:1-10.

17. Angulo P, Hui JM, Marchesini G, et al. Noninvasive tests accurately identify advanced fibrosis due to NASO: baseline data from the stellar trials. Hepatology 2019;70:1521–30.

18. Papathodoridis M, Hiriart JB, Lupusor-Platon M, et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J Hepatol 2021;74:1109–16.

19. Davison AC, Hinkley D.V. Bootstrap methods and their application. Cambridge University Press, 1997.

20. Pettas S, Wong W-S, Camma C, et al. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. Hepatology 2017;65:1145–55.

21. Anstee QM, Lautz EJ, Alkhouli N, et al. Noninvasive tests accurately identify advanced fibrosis due to NASO: baseline data from the stellar trials. Hepatology 2019;70:1521–30.

22. 22 Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2019;156:1717–30.

23. Inadomi C, Takahashi H, Ogawa Y, et al. Accuracy of the enhanced liver fibrosis test, a combination of the enhanced liver fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease. Hepatol Res 2020;50:682–92.

24. Siddiqui MS, Vuppalanichi R, Van Nalla ML, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2019;17:156–63.

25. Hui C, Gaussey C, Imajo K, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol 2019;17:630–7.

26. Chen J, Yin M, Talwalkar JA, et al. Diagnostic performance of MR elastography and Vibration-controlled transient elastography in the detection of hepatic fibrosis in patients with severe to morbid obesity. Radiology 2017;283:418–28.

27. Myers RP, Pomer-Laynages G, Kirsch R, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012;55:199–208.

28. Boursier J, Guillaume M, Leroy V, et al. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD. J Hepatol 2019;71:389–96.

29. Ioannou GN, Feld JJ. What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection? Gastroenterology 2019;156:446–60.

30. Pettis S, Wai-Sun Wong V, Bugianesi E, et al. Impact of obesity and alanine aminotransferase levels on the diagnostic accuracy for advanced liver fibrosis of noninvasive tests in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2019;114:916–28.

31. Woo SK, Kim W, Kim D, et al. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease. Liver Int 2018;38:331–41.

32. Alkayali T, Qurani J, Kaya E, et al. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease. Acta Diabetol 2020;57:613–8.

33. Eren F, Kaya E, Yilmaz Y. Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease. according to body mass index; failure in the prediction of advanced fibrosis in lean and morbidly obese individuals. Eur J Gastroenterol Hepatol. 2017;29:926–33.

34. McPherson S, Hardy T, Dufour JF, et al. As fibrosis grading factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol 2017;112:740–51.

35. Katz and Massand J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6:66.

36. Lichtinghagen R, Pietsch D, Bantel H, et al. The enhanced liver fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol 2013;59:236–42.

37. Newsome PN, Sasso M, Deeks JJ, et al. A composite biomarker using multiparametric activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020;5:362–73.

38. Harrison SA, Ratziu V, Boursier J, et al. A blood-based biomarker panel (NIS4) for non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020;5:362–73.

39. Harrisson SA, Ratziu V, Boursier J, et al. A blood-based biomarker panel (NIS4) for non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020;5:362–73.

40. Dennis A, Moucht S, Kelly M, et al. A composite biomarker using multiparametric activity and fibrosis score: normal values, influence factors and proposed cut-off values. J Hepatol 2013;59:236–42.

41. Agrawal S, Ahiql A, Faisal ST, et al. Visual morphology and three non-invasive markers in the evaluation of liver fibrosis in chronic liver disease. Scand J Gastroenterol 2017;52:107–15.

42. Akyut UE, Akyuz U, Yesil A, et al. A comparison of FibroMeter™ NAFLD score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. Scand J Gastroenterol 2019;44:1343–8.
